Arcellx (ACLX) 10-Q/A 14 Nov 22 2022 Q1 Quarterly report (amended) Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2022	May 09, 2022
Cover [Abstract]
Document Type	10-Q/A
Amendment Flag	true
Amendment Description	Arcellx, Inc. (the Company) is filing this Amendment No. 1 on Form 10-Q/A (Form10-Q/A) to amend its Quarterly Report on Form 10-Q (the Original Form 10-Q), originally filed with the U.S. Securities and Exchange Commission (SEC) on May 12, 2022, to restate certain items presented in our Original Form 10-Q. This Form 10-Q/A includes restatement of our unaudited condensed consolidated interim financial statements as of and for the three months ended March 31, 2022 and amends certain other information in the Original Form 10-Q as described below in the section titled "Items Amended in the Form 10-Q/A."
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Mar. 31, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q1
Current Fiscal Year End Date	--12-31
Entity Registrant Name	ARCELLX, INC.
Entity Central Index Key	0001786205
Entity File Number	001-41259
Entity Tax Identification Number	47-2855917
Title of 12(b) Security	Common Stock, $0.001 par value per share
Trading Symbol	ACLX
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Shell Company	false
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	25 West Watkins Mill Road
Entity Address, Address Line Two	Suite A
Entity Address, City or Town	Gaithersburg
Entity Address, State or Province	MD
Entity Address, Postal Zip Code	20878
City Area Code	240
Local Phone Number	327-0603
Entity Common Stock, Shares Outstanding		35,736,584

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Assets, Current [Abstract]
Cash and cash equivalents	$ 127,160	$ 30,833
Marketable securities	83,769	73,784
Prepaid expenses and other current assets	13,460	8,192
Total current assets	224,389	112,809
Restricted cash	199	199
Property and equipment, net	9,747	10,318
Operating lease right-of-use assets	3,248
Deferred offering costs		3,172
Prepaid research and development expenses and other long-term assets	9,401	2,284
Total assets	246,984	128,782
Current liabilities:
Accounts payable	1,874	1,333
Accrued liabilities	11,650	13,180
Operating lease liabilities, current portion	737
Deferred rent, current portion		183
Other current liabilities	164	149
Total current liabilities	14,425	14,845
Operating lease liabilities, net of current portion	4,477
Deferred Rent Credit, Noncurrent		1,895
Other Liabilities, Noncurrent	147	178
Total liabilities	19,049	16,918
Redeemable convertible preferred stock:
Redeemable convertible preferred stock		233,379
Stockholders' equity (deficit):
Preferred stock, par value of $0.001 per share; 200,000,000 shares authorized, and no shares issued and outstanding as of March 31, 2022; no shares authorized, issued or outstanding as of December 31, 2021
Common stock, par value of $0.001 per share; 1,000,000,000 shares authorized and 35,718,764 shares issued and outstanding as of March 31, 2022; 185,000,000 shares authorized and 544,210 shares issued and outstanding as of December 31, 2021	36	1
Additional paid-in capital	384,095	8,615
Accumulated other comprehensive loss	(44)	(20)
Accumulated Deficit	(156,152)	(130,111)
Total stockholders' equity (deficit)	227,935	(121,515)
Total liabilities, redeemable convertible preferred stock, and stockholders' equity (deficit)	$ 246,984	128,782
Series A Redeemable Convertible Preferred Stock
Redeemable convertible preferred stock:
Redeemable convertible preferred stock		28,894
Series B Redeemable Convertible Preferred Stock
Redeemable convertible preferred stock:
Redeemable convertible preferred stock		85,367
Series C Redeemable Convertible Preferred Stock
Redeemable convertible preferred stock:
Redeemable convertible preferred stock		$ 119,118

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Preferred stock, par or stated value per share	$ 0.001	$ 0.001
Preferred stock, shares authorized	200,000,000	0
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par or stated value per share	$ 0.001	$ 0.001
Common stock, shares authorized	1,000,000,000	185,000,000
Common stock, shares, issued	35,718,764	544,210
Common stock, shares, outstanding	35,718,764	544,210
Series A Redeemable Convertible Preferred Stock
Temporary equity, par or stated value per share	$ 0.001	$ 0.001
Temporary equity, shares authorized	0	29,795,227
Temporary equity, shares issued	0	5,413,272
Temporary equity, shares outstanding	0	5,413,272
Temporary Equity, Liquidation Preference	$ 0	$ 29,795
Series B Redeemable Convertible Preferred Stock
Temporary equity, par or stated value per share	$ 0.001	$ 0.001
Temporary equity, shares authorized	0	49,402,623
Temporary equity, shares issued	0	8,975,585
Temporary equity, shares outstanding	0	8,975,585
Temporary Equity, Liquidation Preference	$ 0	$ 85,681
Series C Redeemable Convertible Preferred Stock
Temporary equity, par or stated value per share	$ 0.001	$ 0.001
Temporary equity, shares authorized	0	57,224,618
Temporary equity, shares issued	0	10,396,707
Temporary equity, shares outstanding	0	10,396,707
Temporary Equity, Liquidation Preference	$ 0	$ 120,000

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Revenues [Abstract]
Revenue	$ 0	$ 0
Operating expenses:
Research and development	18,057	8,521
General and administrative	8,034	2,761
Total operating expenses	26,091	11,282
Loss from operations	(26,091)	(11,282)
Other income, net	50	1
Net loss	(26,041)	(11,281)
Other comprehensive loss:
Unrealized loss on marketable securities	24	0
Comprehensive loss	$ (26,065)	$ (11,281)
Net loss per share attributable to common stockholders - basic	$ (1.25)	$ (33.45)
Net loss per share attributable to common stockholders - diluted	$ (1.25)	$ (33.45)
Weighted-average common shares outstanding - basic	20,760,722	337,302
Weighted-average common shares outstanding - diluted	20,760,722	337,302

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (unaudited) - USD ($) $ in Thousands	Total	Series A	Series B	Series C	IPO	Private Placement	Common Stock	Common Stock IPO	Common Stock Private Placement	Additional Paid In Capital	Additional Paid In Capital IPO	Additional Paid In Capital Private Placement	Retained Earnings	Accumulated Other Comprehensive Income
Beginning Balance at Dec. 31, 2020	$ (63,720)						$ 1			$ 1,421			$ (65,142)
Beginning Balance, Shares at Dec. 31, 2020							333,658
Temporary Equity, Beginning Balance at Dec. 31, 2020		$ 28,894	$ 85,367
Temporary Equity, Beginning balance, shares at Dec. 31, 2020		5,413,272	8,975,585
Issuance of Series C redeemable convertible preferred stock for cash, Value, net of transaction costs				$ 91,186
Issuance of Series C redeemable convertible preferred stock for cash, shares, net of transaction costs				7,970,812
Issuance of Series C redeemable convertible preferred stock for cash, subscriptions				$ (10,000)
Issuance of common stock from vesting of restricted stock, value	5									5
Issuance of common stock from vesting of restricted stock, shares							7,173
Exercise of stock options, value	7									7
Exercise of stock options, shares							7,522
Share-based compensation	757									757
Net loss	(11,281)												(11,281)
Ending Balance at Mar. 31, 2021	(74,232)						$ 1			2,190			(76,423)
Ending Balance, shares at Mar. 31, 2021							348,353
Temporary Equity, Ending Balance at Mar. 31, 2021		$ 28,894	$ 85,367	$ 91,186
Temporary Equity, Ending balance, Shares at Mar. 31, 2021		5,413,272	8,975,585	7,970,812
Issuance of Series C redeemable convertible preferred stock for cash, subscriptions receivable, ending balance at Mar. 31, 2021				$ (10,000)
Beginning Balance at Dec. 31, 2021	(121,515)						$ 1			8,615			(130,111)	$ (20)
Beginning Balance, Shares at Dec. 31, 2021							544,210
Temporary Equity, Beginning Balance at Dec. 31, 2021	233,379	$ 28,894	$ 85,367	$ 119,118
Temporary Equity, Beginning balance, shares at Dec. 31, 2021		5,413,272	8,975,585	10,396,707
Issuance of common stock, net of transaction costs, value					$ 127,283	$ 9,958		$ 9	$ 1		$ 127,274	$ 9,957
Issuance of common stock , net of transaction costs, shares								9,487,500	590,318
Conversion of preferred stock to common stock, value	233,379						$ 25			233,354
Conversion of preferred stock to common stock, shares							24,785,564
Temporary Equity, Conversion of stock, value		$ (28,894)	$ (85,367)	$ (119,118)
Temporary Equity, Conversion of stock, shares		(5,413,272)	8,975,585	(10,396,707)
Issuance of common stock from vesting of restricted stock, value	107									107
Issuance of common stock from vesting of restricted stock, shares							24,889
Exercise of stock options, value	307									307
Exercise of stock options, shares							286,283
Share-based compensation	4,481									4,481
Unrealized loss on investment	(24)													(24)
Net loss	(26,041)												(26,041)
Ending Balance at Mar. 31, 2022	$ 227,935						$ 36			$ 384,095			$ (156,152)	$ (44)
Ending Balance, shares at Mar. 31, 2022							35,718,764
Temporary Equity, Ending balance, Shares at Mar. 31, 2022		0	0	0

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Series C Redeemable Convertible Preferred Stock
Transaction costs		$ 814
Common Stock | IPO [Member]
Transaction costs	$ 15,029
Common Stock | Private Placement [Member]
Transaction costs	$ 42

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cash flows from operating activities
Net loss	$ (26,041)	$ (11,281)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	263	207
Noncash operating lease expense	60
Amortization of premiums and discounts on marketable securities	110
Share-based compensation	4,481	757
Changes in operating assets and liabilities:
Prepaid expenses and other current and non-current assets	(11,864)	48
Accounts payable and other current liabilities	696	321
Accrued liabilities	(187)	392
Operating lease liabilities	(104)
Deferred rent		49
Net cash used in operating activities	(32,586)	(9,507)
Cash flows from investing activities
Purchases of property and equipment	(467)	(1,066)
Purchases of marketable securities	(27,026)
Proceeds from maturities of marketable securities	16,850
Net cash used in investing activities	(10,643)	(1,066)
Cash flows from financing activities
Proceeds from issuance of common stock (initial public offering), net of transactions costs	129,156
Proceeds from issuance of common stock (private placement), net of transactions costs	10,000
Proceeds from issuance of Series C redeemable convertible preferred stock, net of transaction costs		81,756
Proceeds from the exercise of stock options	429	7
Payments under finance leases	(29)	(121)
Payments of deferred offering costs		(14)
Net cash provided by financing activities	139,556	81,628
Net increase in cash and cash equivalents and restricted cash	96,327	71,055
Cash and cash equivalents and restricted cash, beginning of the year	31,032	46,795
Cash and cash equivalents and restricted cash, end of the period	127,359	117,850
Supplemental disclosures of noncash investing and financing activities:
Purchase of property and equipment included in accounts payable and accrued liabilities	35	$ 238
Deferred offering costs included in accrued liabilities	$ 42

Nature of the Business and Basi

Nature of the Business and Basis of Presentation	3 Months Ended
	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of the Business and Basis of Presentation	1. Nature of the Business and Basis of Presentation Organization Arcellx, Inc. (Arcellx or the Company) was incorporated in Delaware in December 2014 and is headquartered in Gaithersburg, Maryland. The Company is a clinical-stage biopharmaceutical company reimagining cell therapy through the development of innovative therapies for patients with cancer and other incurable diseases. On February 8, 2022, the Company closed its initial public offering (IPO) of 9,487,500 shares of its common stock, including the exercise in full by the underwriters of their option to purchase 1,237,500 additional shares of its common stock, at a public offering price of $ 15.00 per share. The Company received net proceeds of $ 127.3 million, after deducting underwriting discounts and commissions of and other offering expenses paid by the Company of approximately $ 15.0 million. The Company’s common stock began trading on the Nasdaq Global Select Market on February 4, 2022, under the ticker symbol “ACLX.” Liquidity The Company has not commercialized any of its drug candidates and planned commercial operations have not commenced. The Company expects to incur additional operating losses and negative operating cash flows for the foreseeable future as it continues development of drug candidates, including preclinical and clinical testing and regulatory approval prior to commercialization. The Company has not generated any revenue to date from product sales and does not expect to generate any revenues from product sales in the foreseeable future. Even if drug development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. The Company expects that its cash and cash equivalents and marketable securities will be sufficient to fund its operating expenses and capital expenditure requirements into the second half of 2023. The Company has funded its operations primarily with proceeds from public and private offerings of its common and preferred stock. The Company plans to seek additional funding through public or private equity offerings, debt financings, marketing and distribution arrangements, other collaborations, strategic alliances, and licensing arrangements. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into strategic alliances or other arrangements on favorable terms, or at all. The terms of any financing may adversely affect the holdings or the rights of the Company’s stockholders. If the Company is unable to obtain funding, the Company could be required to delay, reduce or eliminate research and development programs, product portfolio expansion or future commercialization efforts, which could adversely affect its business prospects. Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the SEC for interim financial information. Accordingly, they do not include all of the information required by U.S. generally accepted accounting principles for complete financial statements. These condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements and the accompanying notes to our consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the SEC on March 24, 2022. In our management’s opinion, the accompanying condensed consolidated financial statements contain all adjustments, including normal, recurring adjustments, necessary to fairly present our financial position as of March 31, 2022 and December 31, 2021, our condensed consolidated statements of operations and comprehensive loss for the three-month period ended March 2022 and 2021, our condensed consolidated statements of redeemable convertible preferred stock and stockholders’ equity (deficit) for the three-month period ended March 31, 2022 and 2021, and our statements of condensed consolidated cash flows for the three-month period ended March 31, 2022 and 2021. Interim results are not necessarily indicative of results for an entire year. Restatement of Previously Issued Financial Statements The Company has restated its previously reported unaudited condensed consolidated financial statements as of and for the three-month period ended March 31, 2022. The restatement reflects the correction of certain errors made in accounting for the Company’s research and development expenses and related accounts and other immaterial errors as of and for the three-month period ended March 31, 2022. The correction of these errors decreased the Company's net loss by $ 6.3 million. The correction of the aforementioned errors and other immaterial errors reduced the research and development expenses by $ 6.3 million, from $ 24.4 million to $ 18.1 million, during the three-month period ended March 31, 2022, as a result of correcting the expense incurred as part of the Company's arrangements with third-party contract research organizations and contract manufacturing organizations. The following table presents the effect of the restatement on the Company's unaudited condensed consolidated financial statements: (in thousands, except per share amounts) As of and Three Months Ended March 31, 2022 Previously Reported Correction of Error Restated Changes in the balance sheet: Prepaid expenses and other current assets $ 9,974 $ 3,486 $ 13,460 Total current assets 220,903 3,486 224,389 Property and equipment, net 10,127 ( 380 ) 9,747 Prepaid research and development expenses and other long-term assets 8,913 488 9,401 Total assets 243,390 3,594 246,984 Accrued liabilities 14,400 ( 2,750 ) 11,650 Operating lease liabilities, current portion 370 367 737 Total current liabilities 16,808 ( 2,383 ) 14,425 Operating lease liabilities, net of current portion 4,844 ( 367 ) 4,477 Total liabilities 21,799 ( 2,750 ) 19,049 Accumulated deficit ( 162,496 ) 6,344 ( 156,152 ) Total stockholders’ equity 221,591 6,344 227,935 Total liabilities and stockholders’ equity 243,390 3,594 246,984 Changes in the statement of operations and comprehensive loss: Research and development 24,401 ( 6,344 ) 18,057 Total operating expenses 32,435 ( 6,344 ) 26,091 Loss from operations ( 32,435 ) 6,344 ( 26,091 ) Net loss ( 32,385 ) 6,344 ( 26,041 ) Comprehensive loss ( 32,409 ) 6,344 ( 26,065 ) Net loss per share attributable to common stockholders—basic and diluted ( 1.56 ) 0.31 ( 1.25 ) Changes in the statement of cash flows: Net loss ( 32,385 ) 6,344 ( 26,041 ) Depreciation and amortization 416 ( 153 ) 263 Prepaid expenses and other current and non-current assets ( 8,423 ) ( 3,441 ) ( 11,864 ) Accrued liabilities 2,563 ( 2,750 ) ( 187 ) Net cash used in operating activities ( 32,586 ) — ( 32,586 )

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies There have been no material changes to the significant accounting policies disclosed in the Company’s Annual Report on Form 10-K during the three months ended March 31, 2022, except for the adoption of the new lease accounting standard effective January 1, 2022, as discussed below. Leases In February 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standard Update (ASU) 2016-02, Leases ( Topic 842 ) . Topic 842 increases transparency and comparability among organizations by requiring the recognition of lease assets and lease liabilities on the balance sheet and disclosure of key information about leasing arrangements for both lessees and lessors. The Company adopted the new standard effective January 1, 2022 , electing to use the package of practical expedients permitted under the transition guidance which allows for the carry forward of historical lease classification for existing leases on the adoption date and does not require the assessment of existing lease contracts to determine whether the contracts contain a lease or initial direct costs. Prior periods were not retrospectively adjusted. The adoption of this standard resulted in the recogn ition of operating lease right-of-use (ROU) assets in the amount of $ 3.3 million and operating lease liabilities in the amount of $ 5.4 million for operating lease liabilities on the consolidated balance sheet, with a $ 2.1 million reclassification of deferred rent and tenant improvement allowances. There was no cumulative effect adjustment to the opening balance of accumulated deficit as of January 1, 2022. The adoption of this standard did not have an impact on the consolidated statements of operations or cash flows on the effective date. The Company leases office space and certain equipment. If a lease arrangement is determined to exist with a lease term of more than 12 months at the lease commencement date, an ROU asset and corresponding lease liability are recorded on the consolidated balance sheet at the lease commencement date based on the present value of lease payments over the lease term. An ROU asset represents the right to control the use of an identified asset over the lease term and a lease liability represents the obligation to make lease payments arising from the lease. The Company uses the discount rate implicit in the lease, if available, or its incremental borrowing rate on the lease commencement date to determine the present value of lease payments. The lease terms used to calculate the ROU assets and related lease liabilities include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Leases are classified as either operating or financing leases based on the economic substance of the agreement. Lease and non-lease components are accounted for together as a single lease component for leases associated with office space. For operating leases, the lease expense is recognized on a straight-line basis over the lease term. For finance leases, the ROU asset is amortized from the lease commencement date to the earlier of the end of the useful life of the ROU asset or the end of the lease term, unless the Company is reasonably certain to exercise an option to purchase the underlying asset or if the lease transfers ownership of the underlying asset to the Company by the end of the lease term, in which case the ROU asset is amortized over the remaining useful life. Interest accretion on the finance lease liabilities is recorded as interest expense. Variable lease expense for both operating and finance leases is expensed as incurred. For short-term lease arrangements with a term of one year or less, the Company has elected to recognize the related lease payments on a straight-line basis over the lease term without recording related ROU assets and lease liabilities.

Restricted Cash

Restricted Cash	3 Months Ended
	Mar. 31, 2022
Cash and Cash Equivalents [Abstract]
Restricted Cash	3. Restricted Cash The Company is required to maintain cash collateral on deposit in a segregated money market bank account, as a condition of a lease agreement. The bank may restrict withdrawals or transfers by, or on behalf of, the Company. The required restricted cash reserve totaled $ 0.2 million as of both March 31, 2022 and December 31, 2021. This amount is presented as restricted cash on the accompanying consolidated balance sheets. The following table reconciles cash and cash equivalents and restricted cash per the balance sheets to the statements of cash flows (in thousands): March 31, March 31, Cash and cash equivalents $ 127,160 $ 117,651 Restricted cash 199 199 Total $ 127,359 $ 117,850

Fair Value of Financial Instrum

Fair Value of Financial Instruments	3 Months Ended
	Mar. 31, 2022
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	4. Fair Value of Financial Instruments The fair value of the Company’s financial assets by level within the fair value hierarchy were as follows (in thousands): March 31, 2022 Level 1 Level 2 Level 3 Money market fund (cash equivalent) $ 124,509 $ — $ — Money market fund (long-term restricted cash) 199 — — Marketable securities: Commercial paper — 50,904 — Corporate debt — 14,797 — U.S. government agency — 15,061 — Asset-backed securities — 3,007 — Total assets measured at fair value $ 124,708 $ 83,769 $ — December 31, 2021 Level 1 Level 2 Level 3 Money market fund (cash equivalent) $ 26,472 $ — $ — Money market fund (long-term restricted cash) 199 — — Marketable securities (1) : Commercial paper — 43,969 — Corporate debt — 17,072 — U.S. government agency — 5,053 — Asset-backed securities — 7,690 — Total assets measured at fair value $ 26,671 $ 73,784 $ — (1) These items have been reclassified to conform to current period presentation. The fair value of financial assets categorized within Level 1 of the fair value hierarchy is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities. The fair value of financial assets categorized within Level 2 of the fair value hierarchy is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data. The Company did not transfer any assets measured at fair value on a recurring basis between levels during the three months ended March 31, 2022 or the year ended December 31, 2021 .

Marketable Securities

Marketable Securities	3 Months Ended
	Mar. 31, 2022
Marketable Securities [Abstract]
Marketable Securities	5. Marketable Securities Available-for-sale marketable securities were as follows (in thousands): March 31, 2022 Amortized Unrealized Unrealized Fair Value Commercial paper $ 50,904 $ — $ — $ 50,904 Corporate debt 14,814 1 ( 18 ) 14,797 U.S. government agency 15,081 — ( 20 ) 15,061 Asset-backed securities 3,013 — ( 6 ) 3,007 Total $ 83,812 $ 1 $ ( 44 ) $ 83,769 December 31, 2021 (1) Amortized Unrealized Unrealized Fair Value Commercial paper $ 43,969 $ — $ — $ 43,969 Corporate debt 17,084 — ( 12 ) 17,072 U.S. government agency 5,056 — ( 3 ) 5,053 Asset-backed securities 7,695 — ( 5 ) 7,690 Total $ 73,804 $ — $ ( 20 ) $ 73,784 (1) These items have been reclassified to conform to current period presentation. All of the Company’s available-for-sale debt marketable securities held as of March 31, 2022 had contractual maturities of less than one year . The Company had 9 securities in an unrealized loss position with an aggregate related fair value of $ 24.8 million as of March 31, 2022. All securities in an unrealized loss position as of March 31, 2022 had been in a loss position for less than 12 months. Unrealized losses on available-for-sale marketable securities as of March 31, 2022 were not significant and were primarily due to changes in interest rates, including market credit spreads, and not due to increased credit risks associated with specific securities. Accordingly, no allowance for credit losses related to the Company’s available-for-sale marketable securities was recorded for the three months ended March 31, 2022 . The Company does not intend to sell these securities or expect to be required to sell the investments before recovery of their amortized cost bases, which may be at maturity. The Company recorded interest income of $ 0.2 million, offset by amortization of premium of $ 0.1 million, for the three months ended March 31, 2022 , which is included in other income, net on the condensed consolidated statements of operations and comprehensive loss.

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	3 Months Ended
	Mar. 31, 2022
Prepaid Expense and Other Assets, Current [Abstract]
Prepaid Expenses and Other Current Assets	6. Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consist of the following (in thousands): March 31, December 31, (Restated) Prepaid research and development costs $ 9,830 $ 6,143 Other prepaid expense and current assets 3,630 2,049 Total prepaid expenses and other current assets $ 13,460 $ 8,192

Commitments

Commitments	3 Months Ended
	Mar. 31, 2022
Commitments [Abstract]
Commitments	7. Commitments Pursuant to the manufacturing services agreement with Lonza Houston, Inc. (Lonza) in connection with the development and manufacture of autologous drug product CART-ddBCMA (Lonza Agreement), the Company entered into a statement of work with Lonza (Lonza SOW) in February 2022, for the technology transfer and cGMP manufacturing of CART-ddBCMA and potentially other pipeline products. The term of the Lonza SOW expires December 31, 2024, unless earlier terminated by either party or unless extended due to certain delays or suspensions or by mutual agreement. The Lonza SOW is non-cancellable for the first six months of the term and carries minimum non-cancellable costs including upfront payments, milestone fees, and fixed monthly payments during the related period. Subsequent to the non-cancellable period, the Company may terminate the arrangement for any reason upon 12 months ' prior notification to Lonza. As of March 31, 2022, the Company’s minimum non-cancellable costs payable to Lonza was approximately $ 40.6 million. Variable costs under this arrangement include materials, external testing, and other services. The Company paid $ 5.8 million under this arrangement during the three months ended March 31, 2022 .

Accrued Liabilities

Accrued Liabilities	3 Months Ended
	Mar. 31, 2022
Accrued Liabilities, Current [Abstract]
Accrued Liabilities	8. Accrued Liabilities Accrued liabilities consist of the following (in thousands): March 31, December 31, (Restated) Research and development accrued expenses $ 9,379 $ 6,626 Accrued offering costs — 1,301 Accrued bonus 793 3,429 Other liabilities 1,478 1,824 Total accrued liabilities $ 11,650 $ 13,180

Leases

Leases	3 Months Ended
	Mar. 31, 2022
Leases [Abstract]
Leases	9. Leases The Company leases office and laboratory space in Gaithersburg, Maryland under one lease that has a term that expires in 2030 unless renewed. The lease agreement contains rent escalation, rent abatement clauses, tenant improvement allowances, and optional renewal clauses. The lease agreement also includes variable lease payments, which are primarily related to common area maintenance and utility charges. The Company also has short-term operating leases with a term of one year or less. As of March 31, 2022, the Company had operating l ease ROU assets of $ 3.2 million, current operating lease liabilities of $ 0.7 million, and non-current operating lease liabilities of $ 4.5 million. The Company used a discount rate of 8.2 % in measuring operating lease liabilities. The remaining lease term was 7.8 years as of March 31, 2022. The Company's total operating lease costs were as follows (in thousands): Three Months Ended Operating lease costs $ 163 Short-term lease costs 377 Variable lease costs 14 $ 554 As of March 31, 2022, future minimum operating lease payments were as follows (in thousands): Through December 31, 2022 $ 555 2023 851 2024 872 2025 894 2026 916 2027 939 Thereafter 2,033 Total operating lease payments 7,060 Less: imputed interest ( 1,846 ) Present value of total operating lease liabilities $ 5,214 Supplemental cash flow information related to operating leases is as follows (in thousands): Three Months Ended Cash paid for amounts included in the measurement of operating lease liabilities $ 206 ROU assets obtained in exchange for operating lease liabilities 3,308

Redeemable Convertible Preferre

Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)	3 Months Ended
	Mar. 31, 2022
Equity [Abstract]
Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)	10. Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) Redeemable Convertible Preferred Stock In connection with the Company's IPO, all outstanding shares of the Company’s redeemable convertible preferred stock automatically converted into shares of common stock at the applicable conversion ratio then in effect. The Company's outstanding shares of preferred stock were converted into 24,785,564 shares of common stock. Preferred Stock Subsequent to the IPO, the Company's board of directors has the authority, without further action by the stockholders, to issue shares of preferred stock in one or more series and to fix the rights, preferences, privileges, and restrictions thereof. These rights, preferences, and privileges could include dividend rights, conversion rights, voting rights, redemption rights, liquidation preferences, sinking fund terms, and the number of shares constituting any series or the designation of such series, any or all of which may be greater than the rights of common stock. The issuance of preferred stock could adversely affect the voting power of holders of common stock and the likelihood that such holders will receive dividend payments and payments upon liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing change in our control or other corporate action. Common Stock In addition to the shares of common stock issued and outstanding in connection with the IPO and the subsequent private placement, total shares of common stock issued and outstanding includes shares issued to employees pursuant to the exercise of vested stock options as well as the vesting of early exercised stock options. In order to execute the early exercises, the employees signed a Restricted Stock Purchase Agreement (RSPA) granting the Company, in the case of termination of employment, the rights to repurchase all of the unvested shares at the price paid by the employee for such shares. Based on the share repurchase rights outlined in the RSPA, the Company recorded the proceeds from the early exercises as a liability on the balance sheet. All shares that were early exercised by the employees of the Company are considered legally issued. However, for accounting purposes, only vested shares are considered issued. Below is a reconciliation of shares issued and outstanding: March 31, December 31, Total shares of common stock legally issued and outstanding 35,736,584 544,967 Less: unvested early exercised shares of common stock ( 17,820 ) ( 757 ) Total shares issued and outstanding 35,718,764 544,210 Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company’s stockholders. Common stockholders are entitled to receive dividends, as may be declared by the board of directors, if any. No dividends have been declared or paid by the Company through March 31, 2022. In the event of any liquidation or dissolution of the Company, the holders of common stock are entitled to the assets of the Company legally available for distribution.

Share-Based Compensation

Share-Based Compensation	3 Months Ended
	Mar. 31, 2022
Share-Based Payment Arrangement [Abstract]
Share-Based Compensation	11. Share-Based Compensation The Company’s 2017 Equity Incentive Plan (the 2017 Plan) provided for the grant of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards, to the Company's employees, directors, and consultants. The 2017 Plan terminated one business day prior to effectiveness of the 2022 Equity Incentive Plan (the 2022 Plan) with respect to the grant of future awards. The 2022 Plan became effective on February 3, 2022 and provides for the grant of incentive stock options to the Company's employees and for the grant of nonstatutory stock options, stock appreciation rights, restricted stock, restricted stock units (RSUs), and performance awards to the Company's employees, directors, and consultants. The aggregate number of shares of common stock that may be issued pursuant to equity awards under the 2022 Plan is 4,296,875 shares, plus shares subject to awards granted under the 2017 Plan that expire or otherwise terminate without having been exercised in full or are forfeited to or repurchased by the Company (provided that the maximum number of shares that may be added to the 2022 Plan pursuant to awards under the 2017 Plan is 6,269,300 shares). The number of shares of common stock reserved for issuance under the 2022 Plan shall be cumulatively increased on the first day of each fiscal year, beginning with the Company’s 2023 fiscal year and ending on the ten year anniversary of the date the Company’s board of directors approves the 2022 Plan equal to the least of 4,296,875 shares, 5 % of the total number of shares of common stock outstanding as of the last day of the immediately preceding fiscal year, or a lesser number of shares determined by the administrator of the 2022 Plan. Share-based compensation expense by type of award was as follows (in thousands): Three Months Ended March 31, 2022 2021 Stock options $ 3,030 $ 757 Restricted stock units 696 — Restricted stock units - executive officer 755 — Total share-based compensation expense $ 4,481 $ 757 The Company recognized $ 4.5 million in share-based compensation expense during the three months ended March 31, 2022, of which $ 1.3 million was included in research and development and $ 3.2 million was included in general and administrative in the accompanying condensed consolidated statements of operations. The Company recognized $ 0.8 million in share-based compensation expense during the three months ended March 31, 2021, of which $ 0.2 million was included in research and development and $ 0.6 million was included in general and administrative in the accompanying condensed consolidated statements of operations. Stock Options Stock options granted under the 2017 Plan and the 2022 Plan vest over three or four years and expire after 10 years . The Company uses the Black Scholes option pricing model to determine the grant date fair value of stock options. A summary of stock option activity for awards under the 2017 Plan and the 2022 Plan is presented below: Options Outstanding and Exercisable Number of Weighted Weighted Aggregate (1) Outstanding as of January 1, 2022 5,598,830 $ 5.36 8.9 $ 7,349 Granted 2,829,435 14.87 Forfeited ( 3,504 ) 11.38 Exercised ( 311,172 ) 1.35 Outstanding as of March 31, 2022 8,113,589 $ 8.83 9.1 $ 44,630 Exercisable as of March 31, 2022 1,767,303 $ 4.83 8.1 $ 16,304 (1) The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the estimated fair value of the common stock for the options that were in the money as of March 31, 2022. Restricted Stock Units RSUs granted under the 2022 Plan generally vest annually over three years . The Company uses the market price of the Company’s common shares on the date of grant to determine the fair value of RSUs. A summary of RSU activity for awards under the 2022 Plan is presented below: Number of Weighted Average Grate Date Fair Value Outstanding as of January 1, 2022 — $ — Granted 703,329 15.00 Vested — — Forfeited ( 666 ) 15.00 Outstanding as of March 31, 2022 702,663 $ 15.00 Restricted Stock Units - Executive Officer In June 2021, the Company granted 952,804 RSUs to an executive officer subject to service, performance, and market conditions. In December 2021, the Company added alternative performance conditions for vesting of the same RSUs (the RSU Award). These additional performance conditions provided alternative paths to vesting and the original award from June 2021 and its vesting conditions remained the same, i.e., the original award was not modified. Each RSU granted in the RSU Award entitles the recipient to one share of common stock upon vesting subject to the service, performance, and market conditions. All 952,804 RSUs were outstanding as of March 31, 2022 and December 31, 2021 and no RSUs were vested or exercisable as of March 31, 2022 or December 31, 2021. Service Condition The service condition to vesting of the RSU Award requires the executive officer’s continued employment with the Company through the achievement of any of the performance conditions and the market condition. Performance Condition The performance conditions to vesting of the RSU Award include (i) the consummation of a change in control event as defined in the 2017 Plan (Change in Control), (ii) the consummation of the first firm commitment underwritten public offering covering the offer and sale of Company shares, the consummation of the direct listing or direct placement of Company shares on a publicly traded exchange, or the completion of a merger or consolidation with a special purpose acquisition company in which the shares of the surviving or parent entity are listed on a national securities exchange (IPO), or (iii) a Change in Control following an IPO. Market Condition The market condition to vesting of the RSU Award involves Company value thresholds depending upon which of the three performance condition scenarios is applicable at the time of measurement. The Company value on a C hange in Control is measured on the date of the Change in Control and is the aggregate amount of deal consideration paid at the closing of a Change in Control by an acquiror for the Company shares of common stock in connection with such Change in Control (Change in Control Market Capitalization). Upon a Change in Control, (i) one-sixth of the RSU Award will vest if a minimum Change in Control Market Capitalization of $2.5 billion is achieved, (ii) all of the RSU Award will vest if a $5.0 billion Change in Control Market Capitalization is achieved, and (iii) a portion of the RSU Award will vest based on a straight-line interpolation if a Change in Control Market Capitalization of between $2.5 billion and $5.0 billion is achieved based on a straight-line interpolation. The Company value in the event of an IPO is measured each June 30 and December 31 following an IPO (subject to applicable lock-up period) and represents the Company's Enterprise Value. The Company's Enterprise Value is determined using the total market capitalization of the Company based the average closing trading price of one share of the Company over the 60-day period ending on the day prior to the applicable IPO measurement date, less cash. Upon an IPO, (i) one-sixth of the RSU Award will vest if a minimum Enterprise Value of $2.5 billion is achieved, (ii) all the RSU Award will vest if a $5.0 billion Enterprise Value is achieved, and (iii) a portion of the RSU Award will vest based on a straight-line interpolation if an Enterprise Value of between $2.5 billion and $5.0 billion is achieved. The Company utilized Monte Carlo simulation models to estimate the fair value of the RSU Award on the date of grant in each of the three performance condition scenarios. Upon completion of the IPO in February 2022, the performance condition of the RSU Award was satisfied and the Company began recognizing share-based compensation expense on an accelerated attribution basis over the anticipated service period ( 10 years ) and based on the fair value (aggregate $ 10.3 million) according to the IPO scenario as no other performance condition was deemed probable at the time of the IPO. The Company recogniz ed $ 0.8 million in share-based compensation expense related to this RSU Award during the three months ended March 31, 2022 .

Net Loss Per Share Attributable

Net Loss Per Share Attributable to Common Stockholders	3 Months Ended
	Mar. 31, 2022
Earnings Per Share [Abstract]
Net Loss Per Share Attributable to Common Stockholders	12. Net Loss Per Share Attributable to Common Stockholders The Company’s potentially dilutive securities include options to purchase common stock, unvested shares of restricted common stock, and redeemable convertible preferred stock. The Company's potentially dilutive securities have been excluded from the computation of diluted net loss per share as the effect would be anti-dilutive. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at period end, from the computation of diluted net loss per share attributable to common stockholders for the period indicated because including them would have had an anti-dilutive effect: March 31, 2022 2021 Redeemable convertible preferred stock — 22,359,669 Options to purchase common stock 8,113,589 2,871,594 Unvested shares of restricted common stock from early exercises 17,820 34,647 Restricted stock units 702,663 — Restricted stock units - executive officer 952,804 — Total 9,786,876 25,265,910

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Leases	Leases In February 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standard Update (ASU) 2016-02, Leases ( Topic 842 ) . Topic 842 increases transparency and comparability among organizations by requiring the recognition of lease assets and lease liabilities on the balance sheet and disclosure of key information about leasing arrangements for both lessees and lessors. The Company adopted the new standard effective January 1, 2022 , electing to use the package of practical expedients permitted under the transition guidance which allows for the carry forward of historical lease classification for existing leases on the adoption date and does not require the assessment of existing lease contracts to determine whether the contracts contain a lease or initial direct costs. Prior periods were not retrospectively adjusted. The adoption of this standard resulted in the recogn ition of operating lease right-of-use (ROU) assets in the amount of $ 3.3 million and operating lease liabilities in the amount of $ 5.4 million for operating lease liabilities on the consolidated balance sheet, with a $ 2.1 million reclassification of deferred rent and tenant improvement allowances. There was no cumulative effect adjustment to the opening balance of accumulated deficit as of January 1, 2022. The adoption of this standard did not have an impact on the consolidated statements of operations or cash flows on the effective date. The Company leases office space and certain equipment. If a lease arrangement is determined to exist with a lease term of more than 12 months at the lease commencement date, an ROU asset and corresponding lease liability are recorded on the consolidated balance sheet at the lease commencement date based on the present value of lease payments over the lease term. An ROU asset represents the right to control the use of an identified asset over the lease term and a lease liability represents the obligation to make lease payments arising from the lease. The Company uses the discount rate implicit in the lease, if available, or its incremental borrowing rate on the lease commencement date to determine the present value of lease payments. The lease terms used to calculate the ROU assets and related lease liabilities include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Leases are classified as either operating or financing leases based on the economic substance of the agreement. Lease and non-lease components are accounted for together as a single lease component for leases associated with office space. For operating leases, the lease expense is recognized on a straight-line basis over the lease term. For finance leases, the ROU asset is amortized from the lease commencement date to the earlier of the end of the useful life of the ROU asset or the end of the lease term, unless the Company is reasonably certain to exercise an option to purchase the underlying asset or if the lease transfers ownership of the underlying asset to the Company by the end of the lease term, in which case the ROU asset is amortized over the remaining useful life. Interest accretion on the finance lease liabilities is recorded as interest expense. Variable lease expense for both operating and finance leases is expensed as incurred. For short-term lease arrangements with a term of one year or less, the Company has elected to recognize the related lease payments on a straight-line basis over the lease term without recording related ROU assets and lease liabilities.

Nature of the Business and Ba_2

Nature of the Business and Basis of Presentation (Tables)	3 Months Ended
	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Effect of Restatement on Company's Unaudited Condensed Consolidated Financial Statements	The following table presents the effect of the restatement on the Company's unaudited condensed consolidated financial statements: (in thousands, except per share amounts) As of and Three Months Ended March 31, 2022 Previously Reported Correction of Error Restated Changes in the balance sheet: Prepaid expenses and other current assets $ 9,974 $ 3,486 $ 13,460 Total current assets 220,903 3,486 224,389 Property and equipment, net 10,127 ( 380 ) 9,747 Prepaid research and development expenses and other long-term assets 8,913 488 9,401 Total assets 243,390 3,594 246,984 Accrued liabilities 14,400 ( 2,750 ) 11,650 Operating lease liabilities, current portion 370 367 737 Total current liabilities 16,808 ( 2,383 ) 14,425 Operating lease liabilities, net of current portion 4,844 ( 367 ) 4,477 Total liabilities 21,799 ( 2,750 ) 19,049 Accumulated deficit ( 162,496 ) 6,344 ( 156,152 ) Total stockholders’ equity 221,591 6,344 227,935 Total liabilities and stockholders’ equity 243,390 3,594 246,984 Changes in the statement of operations and comprehensive loss: Research and development 24,401 ( 6,344 ) 18,057 Total operating expenses 32,435 ( 6,344 ) 26,091 Loss from operations ( 32,435 ) 6,344 ( 26,091 ) Net loss ( 32,385 ) 6,344 ( 26,041 ) Comprehensive loss ( 32,409 ) 6,344 ( 26,065 ) Net loss per share attributable to common stockholders—basic and diluted ( 1.56 ) 0.31 ( 1.25 ) Changes in the statement of cash flows: Net loss ( 32,385 ) 6,344 ( 26,041 ) Depreciation and amortization 416 ( 153 ) 263 Prepaid expenses and other current and non-current assets ( 8,423 ) ( 3,441 ) ( 11,864 ) Accrued liabilities 2,563 ( 2,750 ) ( 187 ) Net cash used in operating activities ( 32,586 ) — ( 32,586 )

Restricted Cash (Tables)

Restricted Cash (Tables)	3 Months Ended
	Mar. 31, 2022
Cash and Cash Equivalents [Abstract]
Schedule of Cash and Cash Equivalents and Restricted Cash	The following table reconciles cash and cash equivalents and restricted cash per the balance sheets to the statements of cash flows (in thousands): March 31, March 31, Cash and cash equivalents $ 127,160 $ 117,651 Restricted cash 199 199 Total $ 127,359 $ 117,850

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	3 Months Ended
	Mar. 31, 2022
Fair Value Disclosures [Abstract]
Schedule of Fair Value of Company's Financial Assets	The fair value of the Company’s financial assets by level within the fair value hierarchy were as follows (in thousands): March 31, 2022 Level 1 Level 2 Level 3 Money market fund (cash equivalent) $ 124,509 $ — $ — Money market fund (long-term restricted cash) 199 — — Marketable securities: Commercial paper — 50,904 — Corporate debt — 14,797 — U.S. government agency — 15,061 — Asset-backed securities — 3,007 — Total assets measured at fair value $ 124,708 $ 83,769 $ — December 31, 2021 Level 1 Level 2 Level 3 Money market fund (cash equivalent) $ 26,472 $ — $ — Money market fund (long-term restricted cash) 199 — — Marketable securities (1) : Commercial paper — 43,969 — Corporate debt — 17,072 — U.S. government agency — 5,053 — Asset-backed securities — 7,690 — Total assets measured at fair value $ 26,671 $ 73,784 $ — (1) These items have been reclassified to conform to current period presentation.

Marketable Securities (Tables)

Marketable Securities (Tables)	3 Months Ended
	Mar. 31, 2022
Marketable Securities [Abstract]
Schedule of Available-for-sale Marketable Securities	Available-for-sale marketable securities were as follows (in thousands): March 31, 2022 Amortized Unrealized Unrealized Fair Value Commercial paper $ 50,904 $ — $ — $ 50,904 Corporate debt 14,814 1 ( 18 ) 14,797 U.S. government agency 15,081 — ( 20 ) 15,061 Asset-backed securities 3,013 — ( 6 ) 3,007 Total $ 83,812 $ 1 $ ( 44 ) $ 83,769 December 31, 2021 (1) Amortized Unrealized Unrealized Fair Value Commercial paper $ 43,969 $ — $ — $ 43,969 Corporate debt 17,084 — ( 12 ) 17,072 U.S. government agency 5,056 — ( 3 ) 5,053 Asset-backed securities 7,695 — ( 5 ) 7,690 Total $ 73,804 $ — $ ( 20 ) $ 73,784 (1) These items have been reclassified to conform to current period presentation.

Prepaid Expenses and Other Cu_2

Prepaid Expenses and Other Current Assets (Tables)	3 Months Ended
	Mar. 31, 2022
Prepaid Expense and Other Assets, Current [Abstract]
Schedule of Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets consist of the following (in thousands): March 31, December 31, (Restated) Prepaid research and development costs $ 9,830 $ 6,143 Other prepaid expense and current assets 3,630 2,049 Total prepaid expenses and other current assets $ 13,460 $ 8,192

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	3 Months Ended
	Mar. 31, 2022
Accrued Liabilities, Current [Abstract]
Schedule of Accrued Liabilities	Accrued liabilities consist of the following (in thousands): March 31, December 31, (Restated) Research and development accrued expenses $ 9,379 $ 6,626 Accrued offering costs — 1,301 Accrued bonus 793 3,429 Other liabilities 1,478 1,824 Total accrued liabilities $ 11,650 $ 13,180

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2022
Leases [Abstract]
Operating lease costs	The Company's total operating lease costs were as follows (in thousands): Three Months Ended Operating lease costs $ 163 Short-term lease costs 377 Variable lease costs 14 $ 554
Summary of Future Minimum operating lease payments	As of March 31, 2022, future minimum operating lease payments were as follows (in thousands): Through December 31, 2022 $ 555 2023 851 2024 872 2025 894 2026 916 2027 939 Thereafter 2,033 Total operating lease payments 7,060 Less: imputed interest ( 1,846 ) Present value of total operating lease liabilities $ 5,214
Summary of Supplemental Cash Flow Information Related to Operating Leases	Supplemental cash flow information related to operating leases is as follows (in thousands): Three Months Ended Cash paid for amounts included in the measurement of operating lease liabilities $ 206 ROU assets obtained in exchange for operating lease liabilities 3,308

Redeemable Convertible Prefer_2

Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Tables)	3 Months Ended
	Mar. 31, 2022
Equity [Abstract]
Schedule of Reconciliation of Shares Issued and Outstanding	Below is a reconciliation of shares issued and outstanding: March 31, December 31, Total shares of common stock legally issued and outstanding 35,736,584 544,967 Less: unvested early exercised shares of common stock ( 17,820 ) ( 757 ) Total shares issued and outstanding 35,718,764 544,210

Share-Based Compensation (Table

Share-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2022
Share-Based Payment Arrangement [Abstract]
Schedule of Share-based Compensation Expense	Share-based compensation expense by type of award was as follows (in thousands): Three Months Ended March 31, 2022 2021 Stock options $ 3,030 $ 757 Restricted stock units 696 — Restricted stock units - executive officer 755 — Total share-based compensation expense $ 4,481 $ 757
Summary of Stock Option Activity	A summary of stock option activity for awards under the 2017 Plan and the 2022 Plan is presented below: Options Outstanding and Exercisable Number of Weighted Weighted Aggregate (1) Outstanding as of January 1, 2022 5,598,830 $ 5.36 8.9 $ 7,349 Granted 2,829,435 14.87 Forfeited ( 3,504 ) 11.38 Exercised ( 311,172 ) 1.35 Outstanding as of March 31, 2022 8,113,589 $ 8.83 9.1 $ 44,630 Exercisable as of March 31, 2022 1,767,303 $ 4.83 8.1 $ 16,304 (1) The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the estimated fair value of the common stock for the options that were in the money as of March 31, 2022.
Summary of Restricted Stock Units Activity	A summary of RSU activity for awards under the 2022 Plan is presented below: Number of Weighted Average Grate Date Fair Value Outstanding as of January 1, 2022 — $ — Granted 703,329 15.00 Vested — — Forfeited ( 666 ) 15.00 Outstanding as of March 31, 2022 702,663 $ 15.00

Net Loss Per Share Attributab_2

Net Loss Per Share Attributable to Common Stockholders (Tables)	3 Months Ended
	Mar. 31, 2022
Earnings Per Share [Abstract]
Schedule of Antidilutive Securities Excluded From Computation of Earnings Per Share	March 31, 2022 2021 Redeemable convertible preferred stock — 22,359,669 Options to purchase common stock 8,113,589 2,871,594 Unvested shares of restricted common stock from early exercises 17,820 34,647 Restricted stock units 702,663 — Restricted stock units - executive officer 952,804 — Total 9,786,876 25,265,910

Nature of the Business and Ba_3

Nature of the Business and Basis of Presentation - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended
	Feb. 08, 2022	Mar. 31, 2022	Mar. 31, 2021
Class of Stock [Line Items]
Net loss		$ 26,041	$ 11,281
Research and development expenses		18,057	$ 8,521
Previously Reported
Class of Stock [Line Items]
Net loss		32,385
Research and development expenses		24,401
Correction of Error
Class of Stock [Line Items]
Net loss		(6,344)
Research and development expenses		$ (6,344)
IPO | Common Stock
Class of Stock [Line Items]
Number of shares issued	9,487,500	9,487,500
Additional stock issued during period shares exercised by underwriters with option to purchase	1,237,500
Public offering price per share	$ 15
Net proceeds from initial public offering	$ 127,300
Cash paid for underwriting discounts and commissions and other offering expenses	$ 15,000

Nature of the Business and Ba_4

Nature of the Business and Basis of Presentation - Schedule of Effect of Restatement on Company's Unaudited Condensed Consolidated Financial Statements (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Changes in the balance sheet:
Prepaid expenses and other current assets	$ 13,460		$ 8,192
Total current assets	224,389		112,809
Property and equipment, net	9,747		10,318
Prepaid research and development expenses and other long-term assets	9,401		2,284
Total assets	246,984		128,782
Accrued liabilities	11,650		13,180
Operating lease liabilities, current portion	737
Total current liabilities	14,425		14,845
Operating lease liabilities, net of current portion	4,477
Total liabilities	19,049		16,918
Accumulated Deficit	(156,152)		(130,111)
Total stockholders' equity	227,935	$ (74,232)	(121,515)	$ (63,720)
Total liabilities and stockholders' equity	246,984		$ 128,782
Changes in the statement of operations and comprehensive loss:
Research and development	18,057	8,521
Total operating expenses	26,091	11,282
Loss from operations	(26,091)	(11,282)
Net loss	(26,041)	(11,281)
Comprehensive loss	$ (26,065)	$ (11,281)
Net loss per share attributable to common stockholders - basic	$ (1.25)	$ (33.45)
Net loss per share attributable to common stockholders - diluted	$ (1.25)	$ (33.45)
Changes in the statement of cash flows:
Net loss	$ (26,041)	$ (11,281)
Depreciation and amortization	263	207
Prepaid expenses and other current and non-current assets	(11,864)	48
Accrued liabilities	(187)	392
Net cash used in operating activities	(32,586)	$ (9,507)
Previously Reported [Member]
Changes in the balance sheet:
Prepaid expenses and other current assets	9,974
Total current assets	220,903
Property and equipment, net	10,127
Prepaid research and development expenses and other long-term assets	8,913
Total assets	243,390
Accrued liabilities	14,400
Operating lease liabilities, current portion	370
Total current liabilities	16,808
Operating lease liabilities, net of current portion	4,844
Total liabilities	21,799
Accumulated Deficit	(162,496)
Total stockholders' equity	221,591
Total liabilities and stockholders' equity	243,390
Changes in the statement of operations and comprehensive loss:
Research and development	24,401
Total operating expenses	32,435
Loss from operations	(32,435)
Net loss	(32,385)
Comprehensive loss	$ (32,409)
Net loss per share attributable to common stockholders - basic	$ (1.56)
Net loss per share attributable to common stockholders - diluted	$ (1.56)
Changes in the statement of cash flows:
Net loss	$ (32,385)
Depreciation and amortization	416
Prepaid expenses and other current and non-current assets	(8,423)
Accrued liabilities	2,563
Net cash used in operating activities	(32,586)
Correction of Error
Changes in the balance sheet:
Prepaid expenses and other current assets	3,486
Total current assets	3,486
Property and equipment, net	(380)
Prepaid research and development expenses and other long-term assets	488
Total assets	3,594
Accrued liabilities	(2,750)
Operating lease liabilities, current portion	367
Total current liabilities	(2,383)
Operating lease liabilities, net of current portion	(367)
Total liabilities	(2,750)
Accumulated Deficit	6,344
Total stockholders' equity	6,344
Total liabilities and stockholders' equity	3,594
Changes in the statement of operations and comprehensive loss:
Research and development	(6,344)
Total operating expenses	(6,344)
Loss from operations	6,344
Net loss	6,344
Comprehensive loss	$ 6,344
Net loss per share attributable to common stockholders - basic	$ 0.31
Net loss per share attributable to common stockholders - diluted	$ 0.31
Changes in the statement of cash flows:
Net loss	$ 6,344
Depreciation and amortization	(153)
Prepaid expenses and other current and non-current assets	(3,441)
Accrued liabilities	$ (2,750)

Summary of Significant Accoun_3

Summary of Significant Accounting Policies - Additional Information (Details) - USD ($) $ in Thousands		3 Months Ended
	Jan. 01, 2022	Mar. 31, 2022	Dec. 31, 2021
Accounting Policies [Abstract]
Accounting standards update [Extensible Enumeration]		us-gaap:AccountingStandardsUpdate201602Member
Change in accounting principle, accounting standards update, adopted date		Jan. 01, 2022
Change in accounting principle, accounting standards update, adopted [true false]		true
Operating lease right-of-use assets	$ 3,300	$ 3,248
Operating lease liabilities	5,400	$ 5,214
Reclassification of deferred rent and tenant improvement allowances	$ 2,100

Restricted Cash (Additional Inf

Restricted Cash (Additional Information) (Details) - USD ($) $ in Millions	Mar. 31, 2022	Dec. 31, 2021
Cash and Cash Equivalents [Abstract]
Restricted cash reserve	$ 0.2	$ 0.2

Restricted Cash - Schedule of C

Restricted Cash - Schedule of Cash and Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021	Mar. 31, 2021	Dec. 31, 2020
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]
Cash and cash equivalents	$ 127,160	$ 30,833	$ 117,651
Restricted cash	199		199
Cash, cash equivalents and restricted cash	$ 127,359	$ 31,032	$ 117,850	$ 46,795

Fair Value of Financial Instr_3

Fair Value of Financial Instruments - Schedule of Fair Value of Company's Financial Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Assets
Marketable securities	$ 83,769	$ 73,784	[1]
Level 1 | Recurring
Assets
Money market fund (cash equivalent)	124,509	26,472
Money market fund (long-term restricted cash)	199	199
Total assets measured at fair value	124,708	26,671
Level 2 | Recurring
Assets
Total assets measured at fair value	83,769	73,784
Level 2 | Recurring | Commercial Paper
Assets
Marketable securities	50,904	43,969
Level 2 | Recurring | Corporate Debt
Assets
Marketable securities	14,797	17,072
Level 2 | Recurring | U.S. Government Agency
Assets
Marketable securities	15,061	5,053
Level 2 | Recurring | Asset-Backed Securities
Assets
Marketable securities	$ 3,007	$ 7,690
[1] These items have been reclassified to conform to current period presentation.

Marketable Securities - Schedul

Marketable Securities - Schedule of Available-for-sale Marketable Securities (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021	[1]
Marketable Securities [Line Items]
Amortized costs	$ 83,812	$ 73,804
Gross Unrealized Gains	1
Gross Unrealized Loss	(44)	(20)
Fair Value	83,769	73,784
Commercial Paper
Marketable Securities [Line Items]
Amortized costs	50,904	43,969
Fair Value	50,904	43,969
Corporate Debt
Marketable Securities [Line Items]
Amortized costs	14,814	17,084
Gross Unrealized Gains	1
Gross Unrealized Loss	(18)	(12)
Fair Value	14,797	17,072
U.S. Government Agency
Marketable Securities [Line Items]
Amortized costs	15,081	5,056
Gross Unrealized Loss	(20)	(3)
Fair Value	15,061	5,053
Asset-Backed Securities
Marketable Securities [Line Items]
Amortized costs	3,013	7,695
Gross Unrealized Loss	(6)	(5)
Fair Value	$ 3,007	$ 7,690
[1] These items have been reclassified to conform to current period presentation.

Marketable Securities - Additio

Marketable Securities - Additional Information (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2022 USD ($) Condition
Marketable Securities [Abstract]
Available-for-sale debt marketable securities contractual maturities	less than one year
Number of securities in an unrealized loss position | Condition	9
Aggregate fair value an unrealized loss position	$ 24,800
Allowance for credit losses	0
Interest income	200
Amortization of premium	$ 100

Prepaid Expenses and Other Cu_3

Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Prepaid Expense and Other Assets, Current [Abstract]
Prepaid research and development costs	$ 9,830	$ 6,143
Other prepaid expense and current assets	3,630	2,049
Total prepaid expenses and other current assets	$ 13,460	$ 8,192

Commitments - Additional Inform

Commitments - Additional Information (Details) $ in Millions	3 Months Ended
	Mar. 31, 2022 USD ($)
Commitments [Abstract]
Prior notification period to terminate arrangement	12 months
Minimum non-cancellable costs	$ 40.6
Obligated to pay to Lonza	$ 5.8

Accrued Liabilities - Schedule

Accrued Liabilities - Schedule of Accrued Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Accrued Liabilities, Current [Abstract]
Research and development accrued expenses	$ 9,379	$ 6,626
Accrued offering costs		1,301
Accrued bonus	793	3,429
Other liabilities	1,478	1,824
Total accrued liabilities	$ 11,650	$ 13,180

Leases - Additional Information

Leases - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Jan. 01, 2022	Dec. 31, 2021
Lessee, Lease, Description [Line Items]
Short-term operating lease, term	1 year
Operating lease right-of-use assets	$ 3,248	$ 3,300
Current operating lease liabilities	737
Non-current operating lease liabilities	$ 4,477
Operating lease, discount rate	8.20%
Operating lease, remaining lease term	7 years 9 months 18 days
Office and Laboratory Space | Gaithersburg, Maryland
Lessee, Lease, Description [Line Items]
Lease expiration year	2030

Leases - Summary of Lease Costs

Leases - Summary of Lease Costs (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2022 USD ($)
Leases [Abstract]
Operating lease costs	$ 163
Short-term lease costs	377
Variable lease costs	14
Total operating lease costs	$ 554

Leases - Summary of Future Mini

Leases - Summary of Future Minimum Operating Lease Payments (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Jan. 01, 2022
Leases [Abstract]
Through December 31, 2022	$ 555
2023	851
2024	872
2025	894
2026	916
2027	939
Thereafter	2,033
Total operating lease payments	7,060
Less: imputed interest	(1,846)
Present value of total operating lease liabilities	$ 5,214	$ 5,400

Leases - Supplemental Cash Flow

Leases - Supplemental Cash Flow Information Related to Operating Leases (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2022 USD ($)
Lessee Disclosure [Abstract]
Cash paid for amounts included in the measurement of operating lease liabilities	$ 206
ROU assets obtained in exchange for operating lease liabilities	$ 3,308

Redeemable Convertible Prefer_3

Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) - Additional Information (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2022 USD ($) shares
Class of Stock [Line Items]
Common stock voting rights	one vote
Common Stock
Class of Stock [Line Items]
Dividends declared or paid | $	$ 0
IPO | Redeemable Convertible Preferred Stock
Class of Stock [Line Items]
Shares issued upon conversion of preferred stock | shares	24,785,564

Redeemable Convertible Prefer_4

Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) - Schedule of Reconciliation of Shares Issued and Outstanding (Details) - Common Stock - shares	Mar. 31, 2022	Dec. 31, 2021
Class of Stock [Line Items]
Total shares of common stock legally issued and outstanding	35,736,584	544,967
Less: unvested early exercised shares of common stock	(17,820)	(757)
Total shares issued and outstanding	35,718,764	544,210

Share-Based Compensation - Addi

Share-Based Compensation - Additional Information (Details) $ in Thousands	1 Months Ended	3 Months Ended		12 Months Ended
	Jun. 30, 2021 shares	Mar. 31, 2022 USD ($) Condition shares	Mar. 31, 2021 USD ($)	Dec. 31, 2021 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense | $		$ 4,481	$ 757
2022 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		3 years
Restricted stock units, granted		4,296,875
2017 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock units, outstanding		6,269,300
Board of Directors
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Anniversary period		10 years
Board of Directors | 2022 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock units, granted		4,296,875
Percentage increase in common stock reserve for future issuance		5%
Research and Development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense | $		$ 1,300	200
General and Administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense | $		3,200	600
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense | $		$ 3,030	$ 757
Stock Options | 2017 and 2022 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period		10 years
Stock Options | 2017 and 2022 Equity Incentive Plan | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		3 years
Stock Options | 2017 and 2022 Equity Incentive Plan | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		4 years
Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense | $		$ 696
Restricted Stock Units | 2022 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock units, granted		703,329
Restricted stock units, outstanding		702,663
Restricted Stock Units | Executive Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense | $		$ 755
Restricted stock units, granted	952,804
Vesting description		Each RSU granted in the RSU Award entitles the recipient to one share of common stock upon vesting subject to the service, performance, and market conditions.
Restricted stock units, outstanding		952,804		952,804
Restricted stock units, vested		0		0
Restricted stock units, exercisable		0		0
Number of performance condition scenarios | Condition		3
Restricted Stock Units | IPO | Executive Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting description		Upon an IPO, (i) one-sixth of the RSU Award will vest if a minimum Enterprise Value of $2.5 billion is achieved, (ii) all the RSU Award will vest if a $5.0 billion Enterprise Value is achieved, and (iii) a portion of the RSU Award will vest based on a straight-line interpolation if an Enterprise Value of between $2.5 billion and $5.0 billion is achieved.
Anticipated service period		10 years
Fair value of the RSU award | $		$ 10,300
Restricted Stock Units | Change in Control | Executive Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting description		Upon a Change in Control, (i) one-sixth of the RSU Award will vest if a minimum Change in Control Market Capitalization of $2.5 billion is achieved, (ii) all of the RSU Award will vest if a $5.0 billion Change in Control Market Capitalization is achieved, and (iii) a portion of the RSU Award will vest based on a straight-line interpolation if a Change in Control Market Capitalization of between $2.5 billion and $5.0 billion is achieved based on a straight-line interpolation.
Restricted Stock Units | General and Administrative | Executive Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense | $		$ 800

Share-Based Compensation - Sche

Share-Based Compensation - Schedule of Share-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total share-based compensation expense	$ 4,481	$ 757
Stock Options
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total share-based compensation expense	3,030	$ 757
Restricted Stock Units
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total share-based compensation expense	696
Restricted Stock Units | Executive Officer
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total share-based compensation expense	$ 755

Share-Based Compensation - Summ

Share-Based Compensation - Summary of Stock Option Activity (Details) - Stock Options - 2017 and 2022 Equity Incentive Plan - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended	12 Months Ended
		Mar. 31, 2022	Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Outstanding, Beginning balance		5,598,830
Number of Shares, Granted		2,829,435
Number of Shares, Forfeited		(3,504)
Number of Shares, Exercised		(311,172)
Number of Shares, Outstanding, Ending balance		8,113,589	5,598,830
Number of Shares, Exercisable		1,767,303
Weighted Average Exercise Price, Outstanding, Beginning balance		$ 5.36
Weighted Average Exercise Price, Granted		14.87
Weighted Average Exercise Price, Forfeited		11.38
Weighted Average Exercise Price, Exercised		1.35
Weighted Average Exercise Price, Outstanding, Ending balance		8.83	$ 5.36
Weighted Average Exercise Price, Exercisable		$ 4.83
Weighted Average Remaining Contractual Life (Years), Outstanding		9 years 1 month 6 days	8 years 10 months 24 days
Weighted Average Remaining Contractual Life (Years), Exercisable		8 years 1 month 6 days
Aggregate Intrinsic Value, Outstanding	[1]	$ 44,630	$ 7,349
Aggregate Intrinsic Value, Exercisable	[1]	$ 16,304
[1] The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the estimated fair value of the common stock for the options that were in the money as of March 31, 2022.

Share-Based Compensation - Su_2

Share-Based Compensation - Summary of Restricted Stock Units Activity (Details) - 2022 Equity Incentive Plan	3 Months Ended
	Mar. 31, 2022 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Granted	4,296,875
Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Granted	703,329
Number of Shares, Forfeited	(666)
Number of Shares, Outstanding, Ending balance	702,663
Weighted Average Grant Date Fair Value, Granted | $ / shares	$ 15
Weighted Average Grant Date Fair Value, Forfeited | $ / shares	15
Weighted Average Grant Date Fair Value, Outstanding, Ending Balance | $ / shares	$ 15

Net Loss Per Share Attributab_3

Net Loss Per Share Attributable to Common Stockholders - Summary of Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details) - shares	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount	9,786,876	25,265,910
Redeemable Convertible Preferred Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount		22,359,669
Options to Purchase Common Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount	8,113,589	2,871,594
Unvested Shares of Restricted Common Stock from Early Exercises
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount	17,820	34,647
Restricted Stock Units
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount	702,663
Restricted stock units - executive officer
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount	952,804